Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M

Valion Bio, Inc.

2024-Q3 EPS reported -$1.07 revenue$600,000

Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.
Net loss in Q3 2024 was $1.4M vs $1.8M in Q3 2023; operating expenses cut $1.9M YTD.
Cash at Sep 30: $2.2M; raised $775K net in Oct-Nov via stock sales.
Completed Phase 1a optimization study for non-invasive VNS; partnered with Fletcher Spaght.
Appointed Lisa Wolf as interim CFO effective Oct 1; supply chain redesigned for higher margins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.